MDMA
News You Might Have Missed: Dec 18th, 2023
Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed
The post News You Might…
Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed
MindMed Announces Positive Results from Phase 2b Anxiety Trial
Big news for LSD fans and MindMed investors as the Phase 2b trial met its primary endpoint, with 50% clinical remission rate in the 100 µg dose group at Week 4
MM-120 (MindMed’s form of LSD) at 100 µg demonstrated a clinically and statistically significant HAM-A reduction of 21.3 points, representing a 7.6-point improvement over placebo
The company plans to hold an End-of-Phase 2 meeting with the FDA and initiate a Phase 3 clinical program in the second half of 2024
MAPS Files New Drug Application With FDA for MDMA-Assisted Therapy
“The filing of our NDA is the culmination of more than 30 years of clinical research, advocacy, collaboration and dedication to bring a potential new option to adults living with PTSD, a patient group that has experienced little innovation in decades,” said Amy Emerson, chief executive officer, MAPS PBC. “If approved, MDMA-assisted therapy would be the first psychedelic-assisted therapy, which we hope will drive additional investment into new research in mental health.”
Tryp Therapeutics To Be Acquired by Exopharm
Tryp Therapeutics Announces Signing of Definitive Agreement with Exopharm Limited. The deal closes with a purchase price of CAD$0.08 per share. Tryp shareholders are expected to receive 4.52 Exopharm Shares for each one Tryp share held, representing a transaction value of approximately $12.8 million.
US Congress Adds Psychedelics Studies to Defense Bill
Abipartisan group of congressional lawmakers from both the House and the Senate have agreed to add funding for studies of psychedelic therapies into a major defense bill.
The 2024 National Defense Authorization Act (NDAA) passed on Wednesday and included the provision for psychedelics research introduced by Republican lawmakers like Rep. Morgan Luttrell of Texas.
Delix Presents Interim Data From Phase I Trial of Novel Neuroplastogen
“While ketamine and serotonergic psychedelics have shown promise for treating certain neuropsychiatric disorders, they are also associated with troublesome side effects and cardiac risks,” said Aaron Koenig, MD, Chief Medical Officer of Delix Therapeutics. “We are encouraged by our preliminary Phase 1 results, which indicate that DLX-001 is safe, well-tolerated, and, as predicted by our preclinical studies, does not produce hallucinogenic, psychotomimetic, or dissociative effects…”
Phase 2 Trial of DLX-001 Expected to Begin in mid-2024
Want to catch up on more industry news? Check out a previous edition of the News You Might Have Missed
The post News You Might Have Missed: Dec 18th, 2023 appeared first on Microdose.
mdma lsd ketamine psychedelic therapeutics therapy anxiety ptsd hallucinogenic psychedelics investors shares funding deal authorization fda research-
Law & Regulation1 week ago
Clearmind signs agreement with Hebrew University for psychedelic compound rights
-
Psychedelics1 week ago
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
-
Psilocybin1 week ago
California advances bill for psychedelics centers
-
Psilocybin4 days ago
Passover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics1 week ago
Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
-
Psychedelics1 week ago
Psychedelics Can Offer More Than Therapy On Its Own
-
Psychedelics4 days ago
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Psychedelics5 days ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID